依维莫司
医学
渡线
临床试验
肾细胞癌
肿瘤科
对数秩检验
交叉研究
加权
总体生存率
内科学
随机对照试验
生存分析
安慰剂
计算机科学
放射科
病理
人工智能
替代医学
作者
Pasi Korhonen,Emmanuel Zuber,Michael Branson,Norbert Hollaender,Nigel A. Yateman,T. Katiskalahti,David Lebwohl,T Haas
标识
DOI:10.1080/10543406.2011.592233
摘要
Clinical trials in oncology often allow patients randomized to placebo to cross over to the active treatment arm after disease progression, leading to underestimation of the treatment effect on overall survival as per the intention-to-treat analysis. We illustrate the statistical aspects and practical use of the rank-preserving structural failure time (RPSFT) model with the Fleming–Harrington family of tests to estimate the crossover-corrected treatment effect, and to assess its sensitivity to various weighting schemes in the RECORD-1 trial. The results suggest that the benefit demonstrated in progression-free survival is likely to translate into a robust overall survival benefit.
科研通智能强力驱动
Strongly Powered by AbleSci AI